Trial Profile

Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Hepatic fibrosis; Liver cirrhosis; Non-alcoholic steatohepatitis
Focus Therapeutic Use
Sponsors Novo Nordisk

24 Jun 2023 Data from 3 studies were taken from NCT03357380, NCT02970942 & NCT03987451 assessing the impact of T2D and other cardiometabolic parameters on weight loss presented at the European Association for the Study of the Liver Congress 2023.
26 Jun 2022 Results assessing efficacy and safety of semaglutide in patients with non-- alcoholic steatohepatitis-related cirrhosis, presented at The International Liver Congress 2022.
08 Jul 2021 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com